알레르기 치료제 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 형태, 최종 사용자, 모드, 단계

The global Allergy Therapeutics Market is projected to grow from $26.1 billion in 2025 to $46.4 billion by 2035, at a compound annual growth rate (CAGR) of 5.9%. The global Allergy Therapeutics Market continues to expand due to the increasing prevalence of allergic diseases, improved diagnostic capabilities, and broader adoption of immunotherapy. According to the World Health Organization (WHO), allergic diseases affect hundreds of millions of people worldwide, while asthma impacts over 260 million individuals globally. The European Academy of Allergy and Clinical Immunology (EAACI) estimates that more than 150 million Europeans currently experience chronic allergic conditions, with prevalence continuing to rise. Industry assessments indicate the market is projected to register a healthy compound annual growth rate exceeding 6% through the forecast period, supported by expanding biologic therapies, personalized immunotherapy, and improved healthcare access.

The product segment includes tablets, inhalers, nasal sprays, eye drops, skin creams, injectables, and sublingual immunotherapy formulations developed to manage allergic reactions and modify disease progression. Tablets and inhalers remain widely prescribed for allergic rhinitis and asthma, while nasal sprays and eye drops provide targeted symptom relief. Skin creams address allergic dermatitis, whereas injectable and sublingual immunotherapy products offer long-term immune tolerance by gradually desensitizing patients to allergens. Continuous pharmaceutical innovation, improved patient compliance, expanding biologics development, and increasing prevalence of chronic allergies are strengthening product demand and supporting sustained market expansion globally.

The services segment comprises allergy testing, consultation services, immunotherapy services, and pharmacy services that collectively support comprehensive allergy management. Allergy testing identifies specific allergens using skin prick, patch, blood, and molecular diagnostic techniques, enabling personalized treatment strategies. Consultation services facilitate disease monitoring and treatment optimization, while immunotherapy services provide supervised administration of allergen-specific therapies. Pharmacy services improve medication accessibility, patient education, and adherence. Increasing adoption of precision medicine, digital healthcare platforms, multidisciplinary allergy clinics, and preventive care models is expanding service utilization and creating long-term opportunities across developed and emerging healthcare systems.

Geographical Overview

North America accounts for a significant share of the Allergy Therapeutics Market owing to its advanced healthcare infrastructure, extensive allergy diagnosis network, high awareness among patients, and favorable reimbursement frameworks. The region benefits from strong pharmaceutical innovation, widespread availability of biologics, established immunotherapy practices, and continuous clinical research activities. Rising prevalence of allergic asthma, food allergies, eczema, and allergic rhinitis continues to increase treatment demand. Government-supported healthcare initiatives, active participation of biotechnology companies, robust regulatory pathways, and significant investments in allergy research further reinforce regional market leadership and encourage continuous product commercialization.

Asia-Pacific is experiencing substantial expansion driven by urbanization, environmental pollution, changing lifestyles, and increasing incidence of respiratory and food allergies. Governments are investing in healthcare modernization, diagnostic laboratories, and specialty allergy clinics to improve disease management. Pharmaceutical companies continue expanding manufacturing facilities, distribution networks, and clinical trial activities throughout the region. Rising disposable incomes, growing health awareness, expanding insurance coverage, and improved access to innovative therapies are supporting adoption of advanced allergy therapeutics. The large patient population and ongoing healthcare reforms position the region for sustained long-term market development.

Key Trends and Drivers

Technological Advancements in Immunotherapy:

The Allergy Therapeutics Market is experiencing significant growth due to advancements in immunotherapy technologies. These innovations include the development of sublingual immunotherapy (SLIT) and novel biologics that offer more targeted and effective treatment options. The integration of digital health tools and wearable devices is also enhancing patient monitoring and adherence, leading to improved outcomes. As technology continues to evolve, it is expected to drive further adoption of personalized allergy treatments, catering to the specific needs of individual patients.

Rising Allergy Burden Accelerates Treatment Demand:

The rising global burden of allergic disorders remains the primary driver of market expansion. Increasing exposure to environmental pollutants, climate-related changes, urban lifestyles, dietary modifications, and genetic susceptibility has contributed to the growing incidence of allergic rhinitis, asthma, atopic dermatitis, and food allergies. Simultaneously, improved diagnostic technologies, greater patient awareness, favorable healthcare expenditure, and expanding availability of innovative biologics and immunotherapy solutions continue to strengthen treatment adoption across both developed and emerging markets.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Form
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Immunotherapy
  • 4.1.2 Antihistamines
  • 4.1.3 Decongestants
  • 4.1.4 Corticosteroids
  • 4.1.5 Mast Cell Stabilizers
  • 4.1.6 Leukotriene Inhibitors
  • 4.1.7 Biologics
  • 4.1.8 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Tablets
  • 4.2.2 Inhalers
  • 4.2.3 Nasal Sprays
  • 4.2.4 Eye Drops
  • 4.2.5 Injectables
  • 4.2.6 Topical Creams
  • 4.2.7 Sublingual Drops
  • 4.2.8 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consultation
  • 4.3.2 Diagnosis
  • 4.3.3 Allergy Testing
  • 4.3.4 Immunotherapy Services
  • 4.3.5 Pharmacy Services
  • 4.3.6 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Recombinant DNA Technology
  • 4.4.2 Monoclonal Antibody Technology
  • 4.4.3 CRISPR
  • 4.4.4 Gene Therapy
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Asthma
  • 4.5.2 Allergic Rhinitis
  • 4.5.3 Food Allergy
  • 4.5.4 Skin Allergy
  • 4.5.5 Drug Allergy
  • 4.5.6 Anaphylaxis
  • 4.5.7 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Clinics
  • 4.6.3 Homecare Settings
  • 4.6.4 Research Institutes
  • 4.6.5 Pharmacies
  • 4.6.6 Others
• 4.7 Market Size & Forecast by Form (2020-2035)
  • 4.7.1 Solid
  • 4.7.2 Liquid
  • 4.7.3 Semi-Solid
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 Prescription-based
  • 4.8.2 Over-the-Counter
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Preclinical
  • 4.9.2 Clinical Trials
  • 4.9.3 Commercialized
  • 4.9.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Form
    • 5.2.1.8 Mode
    • 5.2.1.9 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Form
    • 5.2.2.8 Mode
    • 5.2.2.9 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Form
    • 5.2.3.8 Mode
    • 5.2.3.9 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Form
    • 5.3.1.8 Mode
    • 5.3.1.9 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Form
    • 5.3.2.8 Mode
    • 5.3.2.9 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Form
    • 5.3.3.8 Mode
    • 5.3.3.9 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Form
    • 5.4.1.8 Mode
    • 5.4.1.9 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Form
    • 5.4.2.8 Mode
    • 5.4.2.9 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Form
    • 5.4.3.8 Mode
    • 5.4.3.9 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Form
    • 5.4.4.8 Mode
    • 5.4.4.9 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Form
    • 5.4.5.8 Mode
    • 5.4.5.9 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Form
    • 5.4.6.8 Mode
    • 5.4.6.9 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Form
    • 5.4.7.8 Mode
    • 5.4.7.9 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Form
    • 5.5.1.8 Mode
    • 5.5.1.9 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Form
    • 5.5.2.8 Mode
    • 5.5.2.9 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Form
    • 5.5.3.8 Mode
    • 5.5.3.9 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Form
    • 5.5.4.8 Mode
    • 5.5.4.9 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Form
    • 5.5.5.8 Mode
    • 5.5.5.9 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Form
    • 5.5.6.8 Mode
    • 5.5.6.9 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Form
    • 5.6.1.8 Mode
    • 5.6.1.9 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Form
    • 5.6.2.8 Mode
    • 5.6.2.9 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Form
    • 5.6.3.8 Mode
    • 5.6.3.9 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Form
    • 5.6.4.8 Mode
    • 5.6.4.9 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Form
    • 5.6.5.8 Mode
    • 5.6.5.9 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 GlaxoSmithKline
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Sanofi
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Merck
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Allergy Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 ALK-Abello
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Stallergenes Greer
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Aimmune Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 HAL Allergy
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Novartis
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Johnson & Johnson
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Pfizer
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 AstraZeneca
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Boehringer Ingelheim
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Roche
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Teva Pharmaceutical Industries
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Bayer
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Mylan
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Takeda Pharmaceutical
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Amgen
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Regeneron Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us